WA
WuXi AppTec's Corporate Venture Fund
WuXi AppTec's Corporate Venture Fund is a Series A to Series C stage investment firm. It has made 5 investments. 40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (40% of deals). Average disclosed round size is $66.2M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series C
Last 12 Mo
0
Team
LH
Lennart H. Lee
Responsible for deal sourcing, execution and portfolio management
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 D3 Bio | Unknown | $62M | Apr 2024 |
 Immunocore | Series B | $140M | Apr 2020 |
| XXW Laboratories | Series C | $58M | Jan 2020 |
| MMagnolia Neurosciences | Series A | $31M | Aug 2018 |
| RRGENIX | Series C | $40M | Jan 2015 |
Top Co-Investors
Alexandria Venture Investments2 shared
Eli Lilly and Company2 shared
Panacea Venture1 shared
WuXi AppTec1 shared
WI Harper Group1 shared
KTB Network1 shared
Matrix Partners China1 shared
Medicxi1 shared
AbbVie1 shared
ARCH Venture Partners1 shared
Pfizer Ventures1 shared
+ND Capital1 shared
Sofinnova Partners1 shared
Novo Capital1 shared
Novo Holdings A/S1 shared
General Atlantic1 shared
Omega Funds1 shared
Rock Springs Capital1 shared
Last updated: 27 September 2026